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Exosomes are tiny membrane-bound vesicles that are over produced by most proliferating cell types during normal
and pathological states. Their levels are up-regulated during pregnancy and disease states such as cancer. Exosomes
contain a wide variety of proteins, lipids, RNAs, non-transcribed RNAs, microRNAs and small RNAs that are represen-
tative to their cellular origin and shuttle from a donor cell to a recipient cell. From intercellular communication to
tumor proliferation, exosomes carry out a diverse range of functions, both helpful and harmful. Useful as biomarkers,
exosomes may be applicable in diagnostic assessments as well as cell-free anti-tumor vaccines. Exosomes of ovarian
cancer contain different set of proteins and miRNAs compared to exosomes of normal, cancer-free individuals.
These molecules may be used as multiple “barcode” for the development of a diagnostic tool for early detection of
ovarian cancer.
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Exosomes, like the intraluminal vesicles range approxi-
mately from 30-100 nm in diameter secreted by live cells
and were first observed in the early 1980s. Secretion of exo-
somes from cells was proposed to be a mechanism through
which cells discard their garbage [1-4]. However, in recent
years, exosomes have emerged as important molecules for
inter-cellular communication that are involved both in nor-
mal and in pathophysiological conditions, such as lactation
[5], immune response [6] and neuronal function [5], and
also in the development and progression of diseases such as
liver disease [7], neurodegenerative diseases [8] and cancer
[9,10]. They exhibit a round, saucer-like morphology and
are encapsulated by a lipid bilayer [10,11]. Exosomes are
found in higher concentrations in the peripheral circulation
during pregnancy and cancer [12]. A large number of bio-
logical functions of exosomes have been demonstrated
however, in this review we will focus discussing on the
functions of exosomes in ovarian cancer and immune toler-
ance related to cancer.* Correspondence: sskaka01@louisville.edu
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stated.Exosome biogenesis and secretion
Exosomes in eukaryotic cells, throughout their life cycle
periodically engulf small amounts of intracellular fluid,
forming a small intracellular body called an endosome
[13,14]. As the early endosome matures and develops
into the late endosome, it becomes characterized by the
formation of intraluminal vesicles (ILV) inside the lumen
of the endosome. Ranging from 30-100 nm in diameter,
the ILVs are formed by inward budding of the endoso-
mal membrane, randomly engulfing portions of the cyto-
solic contents and incorporating transmembrane and
peripheral proteins into the invaginating membrane. The
transformation into the late endosome can also be de-
tected by observing a change in its shape and location:
the early endosome is tube-like in shape and is usually
located in the outer portion of the cytoplasm, whereas,
the late endosome is spherical and found closer to the
nucleus [14]. The late endosome containing ILVs is also
called as multivesicular body (MVB) [15,16].
The fate of the MVB may vary. Typically, it fuses with the
lysosome and its contents are degraded by the hydrolysis
inside the lysosome. It has been proposed that the contents
of the MVB are sorted; proteins destined for degradation
by the lysosome and are found in the ILVs, whereas pro-
teins that may have another function or role are found out-
side the ILVs of the MVB. However, the mechanism bytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Possible theories involving the sorting of proteins have been
proposed [17,18].
As an alternative to fusion with the lysosome, the
MVB may fuse with the plasma membrane of the cell in
a proposed ion-dependent manner instead, releasing its
ILVs in an exocytotic fashion to the extracellular envir-
onment (Figure 1). These vesicles are then referred as
exosomes [15]. Demonstrated both in vivo and in vitro,
exosomes are secreted during both normal and patho-
logical conditions and by a wide array of cell types [19].
First discovered in maturing mammalian reticulocyte
(immature red blood cells) exosomes are secreted by
wide range of mammalian cell types, including B and T
cells [20], dendritic cells [16], mesenchymal stem cells
[21], epithelial cells [22,23], astrocytes [24], endothelial
cells [25] and cancer cells [12,26-37]. Exosomes have
also been identified in most bodily fluids including urine
and amniotic fluid [38], blood [39], serum [12,40], saliva
[41,42], ascites [28,43], breast milk [6], cerebrospinal
fluid [44,45] and nasal secretion [46]. Importantly,Figure 1 Biogenesis and release of exosomes: diagram depicted the wcancer cells have been shown to secrete exosomes in
greater amounts than normal cells [12,47].
Exosomes are mainly secreted by two different mecha-
nisms, constitutive release via the Trans-Golgi network
and inducible release [48,49]. Studies from Thery and
colleagues demonstrated that a number of Rab family
proteins, including Rab27a and Rab27b, act as key regu-
lators of exosomes secretion [50]. Apart from Rab 27a
and 27b, another Rab family member, Rab 35 and Rab
11 have also been shown to regulate the secretion of
exosomes by interacting with GTPase-activating protein
TBC1 domain family member 10A-C (TBC1D10A-C)
[51,52]. The Rab family of proteins are often mutated
(constitutively active) or over-expressed in cancer cells.
It has also been shown that activation of the tumor
suppressor protein, p53, stimulates and increases the
rate of exosome secretion by regulating transcription of
the various genes such as TSAP6 and CHMP4C, which
activate exosome production [53]. If the cell experiences
stresses such as hypoxia or toxic stress, DNA may be-
come damaged. The p53 protein responds to thisell-accepted model for exosome biogenesis and release.
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genes (Figure 2). This results in what is known as “by-
stander effect”, during which the cell secretes certain
proteins that communicate with nearby cells to help in
recruiting them for a response to compensate the stress
[54]. Irradiation of human prostate cancer cells strongly
indicated DNA damage that could indeed induce a p53-
dependent increase in exosome secretion by activating
the cells [54]. In addition, secretion of exosomes appears
to be increased by K+-induced depolarization in neur-
onal cells, and the crosslinking of CD3 with T cells, and
intracellular Ca2+ levels [14,15]. Various other stimuli
and change in membrane pH have also been shown to
trigger the secretion of exosomes from various cell types
[55,56].
Once exosomes are released from the parent cells,
they carry out a variety of functions and may eventually
be taken up by another cell [57] (Figure 2). It has been
reported that certain exosomes, such as those that have
been secreted by tumor cells, carry phosphatidylserineFigure 2 Schematic of exosome secretion in a cancer cell model. Exos
Network and/or inducible pathways, which can be activated by p53 and o
Azorsa (19).(PS) on their membranes. PS acts as a signal and has a
large role in exosome uptake by certain cells [58]. When
an exosome is taken up by another cell, the entire exo-
some may be endocytosed and re-legated to clathrin-
coated pits, or may simply release its inner contents into
the cell and remain united with the cell membrane [57].Composition of exosomes
A large amount of exosomal proteins have been identi-
fied, and the consistency among exosomes stemming
from like-cell types suggests that a sorting mechanism is
acting during exosomal development. TSG101 and Alix
have been identified in exosomal analysis and are known
components of the endosomal sorting complex required
for transport (ESCRT) machinery. ESCRT functions to
sort the cargo proteins of ILVs. It works at the endoso-
mal/MVB membrane and recognizes ubiquitinylated
proteins that are associated with tetraspanins and pos-
sibly those which are GPI-anchored, arranges them inomes are secreted via a constitutive pathway involving the Trans-Golgi
ther stimuli such as Rab proteins. Reproduced from Henderson and
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come contents of exosomes [15,17].
The function of the original cell from which an exo-
some originate can be deduced by the makeup of pro-
teins, lipids, miRNAs, mRNA, non-coding RNAs and
other molecules found in a particular exosome. Exo-
somes contain many different cell surface molecules and
are able to engage many different cell receptors simul-
taneously. This allows them to participate in the ex-
change of materials between cells, for example proteins,
lipids, carbohydrates, and pathogens [13]. Recent infor-
mation from different cell type reveals that exosomes
contains 4,563 proteins, 194 lipids, 1639 mRNA and 764
microRNA [59,60] demonstrating their complexity. Exo-
somes are rich in molecules that are involved in antigen
presentation, such as CD1 and the major histocompati-
bility molecules (MHC) class I and II, which play a key
role in immune-regulation by possessing antigenic pep-
tides [61]. MHC I also may be involved in the presenta-
tion of antigen fragments to T cells [62,63]. Also
exosomes contain tetraspanins CD9, CD63, CD81, and
CD82, as well as co-stimulatory molecules (CD86) and
adhesion molecules CD11b and CD54 [33,61,62]. Other
common exosomal proteins include heat shock proteins
HSP70 and HSP90, which expedite peptide loading onto
MHC I and II, as well as play a role in the cellular re-
sponse to environmental stresses. Inside the cell, HSPs
assist in protein folding and trafficking, acting as chaper-
ones [62,63]. Exosomes in general also contain cytoplas-
mic proteins such as annexins and rab proteins, both of
which may promote the fusion of MVB with the cell
membrane and expulsion of exosomes. In the last few
years, exosomes have been reported to contain nucleic
acid such as DNA, RNA, miRNA and none coding RNA
[12,58,59,64-69] in addition to proteins. RNA containing
exosomes may represent alternate pathway of cellular
communication with significant implications in the
modification of cell phenotypes. The mRNAs found in
exosomes are found to be functional and could be trans-
ferred to target cells and translated into proteins [70,71].
Specific miRNA such as let-7, miR-1, miR-15, miR-16,
miR-151 and miR 375 which play role in angiogenesis,
hematopoiesis, exocytosis and tumorigenesis have been
reported in exosomes [65]. Along with DNA, RNA,
miRNA, cytoplasmic tubulin, actin, and actin-binding
proteins are also commonly found in exosomes
[12,58,59]. Membrane proteins CD55 (decay accelerating
factor) and CD59 have been reported in exosomes which
provide protection against the complement system and
thus are an instrumental part in the stability of the exo-
some outside the cell [15]. Exosomes also commonly
contain signal transduction proteins such as G-proteins
and protein kinases [58,59]. In addition, exosomes tend
to have a rich content of proteolysis enzymes, suggestingthat exosomes may increase cell migration [10,13]. It is
to note that exosomes do not contain mitochondrial, nu-
clear, and endoplasmic proteins [13].
Exosomes derived from B cells, T cells, dendritic cells,
intestinal epithelial cells and many other cell types con-
tain specific-proteins pertaining to their particular func-
tions in addition to commonly found proteins in
exosomes. Exosomes secreted by intestinal epithelial
cells display syntaxin 3, C26, and the A33 antigen, de-
pending upon which side of the epithelial membrane it
is released such as apical or basolateral [15]. Exosomes
from T lymphocytes contain many T cell receptors, indi-
cating exosomes role in intercellular communication.
Exosomes secreted by dendritic cells contain CD80 and
CD86 proteins, which are involved in the activation of
naïve CD4+ T cells [10]. Microglial cells appear to re-
lease exosomes, which display CD13, the active amino-
peptidase that cleaves neuropeptides [15]. Some of the
major proteins reported in the exosomes are shown in
Table 1.
Functions of exosomes
Exosomes are involved in many physiological processes,
both beneficial and pathological. Initially, exosomes were
characterized as a means for the maturing reticulocyte
to get rid of superfluous proteins. Studies have now
shown that exosomes are involved in elimination of un-
necessary proteins or unwanted molecules from the cell,
exchange of materials between cells, intercellular com-
munication, propagation of pathogens, functions of the
immune system (both stimulatory and inhibitory), anti-
gen presentation, and many more. By observing the
varying protein contents, it is quite easy to understand
how exosomes that come from different cell types can
have differential functions [13,62] and prove to be highly
useful molecules in various biological functions.
Exosomes in ovarian tumor
There is a paradox about exosomes that some may have
beneficial effects, such as those released from B cells and
dendritic cells. These have powerful anti-tumor and
immune-stimulatory effects and the latter also provides
co-stimulatory proteins that are used to activate T cells
when presented with tumor antigens. On the other
hand, exosomes secreted from tumor cells have been ob-
served to enhance tumor invasiveness and angiogenesis,
while suppressing the immune response [72]. Breast can-
cer tumor-derived exosomes and prostasomes (exosome-
like vesicles released by the prostate) can also promote
angiogenesis in individuals with cancer, whereas prosta-
somes in a healthy individual inhibit angiogenesis, en-
hance sperm motility, and delay and stabilize the
acrosome reaction, as well as act immune suppressive in
its local environment [35,57]. It is not only cancer cell-
Table 1 Some of the common proteins in exosomes
Antigen presentation MVB formation Signal transduction Heat shock Tetraspanin Adhesion molecules
MHC I Alix Gi2a, Gi3a, Gsa, FRL, Erk2, Fyn Hsp70 CD9 CD146, CD166
MHC II TSG101 Hsp84 CD37 ICAM-1, ALCAM
CD86 Gag Sh2 phosphatase Hsp90 CD53 MAC-1, Integrins a3, a4, aM, b1, b2
RhoA, C, GDI CD63
Syntenin, CBL CD81 LFA3, CD53,
Catenin, LCK CD82 CD326
CD11a, b, c
Membrane Cytoskeletal Miscellaneous Lipid Raft Enzymes
Transport & Fusion Proteins Associated
AP-1, Arp2/3, SNAP Radixin Thioredoxine P-Selectin LBPA ATP Citrate lyase
Syntaxin Advillin peroxidase CD18, CD147 Cholesterol ATPase
Clathrin
Dynamin Vimentin Histone 1, 2, 3 Complement factor 3 Flotillin-1 G6P Isomerase
Rab5,7, Rap1B Talin, CAP1 MVP, CD26, CD13 CD55 Stomatin Peroxiredoxin 1
RabGDI Ezrin, Actin CD59 Asp amino- transferase
a-enolase
Annexins (I, II, IV, V, VI) Tubulin Ferritin light chain 1, 2 Aldehyde reductase
Moesin FA Synthase
Cofilin Pyruvate kinase
References: 15, 6, 72,73
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somes secreted by platelets have demonstrated to pro-
mote tumor growth and metastasis of lung cancer cells
[55].
Tumor cell-secreted exosomes include many of the
common exosomal proteins; they also contain tumor an-
tigens that are reflective of the tumors they are derived
from [13]. The heat shock proteins (HSP) found in
tumor exosomes are taken up by dendritic cells and
macrophages, which process and present the HSP to the
lymph nodes. The HSP then release the tumor-specific
antigens they hold, which are presented to cytotoxic T
cells leading to their activation. Studies have demon-
strated the elimination of various cancers using HSP-
stimulated immune cells [62].
Exosomes released by tumor cells are quite unique
and have recently come into the spotlight, with many
groundbreaking discoveries of their unique proteins and
their potential to be diagnostic biomarkers. Tumor exo-
somes are known to have a significant role in the com-
munication and interaction with tumor cells, immune
cells and its surrounding environment. In cancer cells,
exosomes entail the transfer of cancer-promoting cellu-
lar contents to surrounding cells within the tumor
microenvironment or to the circulation to act at distant
sites, thereby enabling cancer progression. Several stud-
ies have demonstrated the presence of exosomes inovarian cancer cell cultures and ovarian cancer patients’
plasma/serum or ascites [12,38,39,43,58,62,63,73-76] in
addition to many other cancers. Three to 4-fold higher
amount of exosomes has been reported in circulation of
patients with ovarian cancer compared to normal indi-
viduals [77]. Ovarian cancer is one of the most lethal
forms of cancer in women, and until recently, lacked
consistent biomarkers useful for its detection. Approxi-
mately 70% of cases of ovarian cancer are diagnosed in
advanced stage, which has only a 20% survival rate
within 5 years of diagnosis. However, if diagnosed at
early stage (at Stage I), survival rate is over 90% [12].
Therefore, early diagnosis using exosomal contents may
be highly important and may save large number of pa-
tients dying from ovarian cancer due to late diagnosis.
Exosomes provide stable, disease-specific markers for
detection, disease characterization, and disease prognosis
[73]. Even though change in exosome content in circula-
tion can be used as a diagnostic tool to detect cancer,
but measuring the content of circulating exosomes is
not very specific and authentic technique. However,
proteomic and genetic profiling of circulating exosomes
can provide better diagnosis and monitoring of thera-
peutic response and diagnostic tool [73].
Recent discoveries of the presence of microRNAs, epithe-
lial cell adhesion molecule (EpCAM) and CD24 in ovarian
tumor-derived exosomes have been highly promising
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is a glycoprotein that facilitates homo-typical adhesion of
cells. It has been found in pseudo-stratified, transitional and
simple epithelia on the basolateral surfaces and has been
identified as a cargo protein in exosomes. EpCAM is
expressed to a certain degree in the normal epithelia of
many organs and is highly overexpressed in multiple types
of carcinomas. The overexpression is correlated with an es-
calation of epithelial cell proliferation, as occurs in tumor
development [66]. Studies by some investigators have used
the magnetic activated cell sorting procedure (MACS)
using magnetic micro-beads coated with EpCAM anti-
bodies to isolate exosomes that specifically express EpCAM
[12,77]. Results from these studies showed very low levels
of EpCAM (0.039+0.030 mg/ml) in exosomes of normal in-
dividuals and an increase in levels related to stage and se-
verity of ovarian carcinoma, reaching a significantly higher
level of 1.42 + 0.228 mg/ml for Stage IV ovarian carcin-
omas. This indicates that EpCAM can be useful as a bio-
marker for the diagnosis of ovarian cancer as well as the
detection of tumor-derived exosomes [12,66]. High
EpCAM concentration is usually associated with a high
concentration of CD24 [43]. CD24 is recognized as a tumor
marker and is associated with poor prognosis of ovarian
carcinomas. It is also expressed by many other types of ma-
lignancies as well as by some normal cell types. CD24 is a
glycoprotein linked to the cell membrane via a GPI-anchor.
CD24 can also be found in the cytoplasm inside MVBs and
released into the extracellular environment via exosomes,
in which case it is correlated with more aggressive forms of
ovarian carcinoma, worsening the prognoses and therefore,
shortening patients’ survival times [43].
Presently, ~2,000 microRNAs have been described in hu-
man [78] microRNAs have been reported to play important
role in in cellular and developmental processes, including
developmental timing, organ development, differentiation,
proliferation, apoptosis and immune regulation [67]. Re-
cently, Taylor and his colleagues reported the presence of
diagnostic miRNAs from EpCAM-positive exosomes from
ovarian cancer patients’ serum [12]. The discoveries for the
presence of microRNAs, EpCAM, and CD24 in ovarian
tumor-derived exosomes have provided promising alterna-
tives to early detection. MicroRNAs are small non-coding
RNAs ([22-25] nucleotides) that are important in the regu-
lation of cellular processes such as differentiation, prolifera-
tion, cell death, and maturation. MicroRNAs from normal
cells and tumor cells of the same tissue type have remark-
ably different makeup. These findings, along with the previ-
ous knowledge of the secretion of exosomes by tumor cells,
have recently led to research that microRNAs may be use-
ful as biomarkers. Ideal microRNAs used for diagnosis pur-
pose would be absent or present at non-detectable level in
the circulating exosomes of cancer-free individuals, but are
aberrantly expressed in ovarian cancer and it is postulatedthat they may be useful in the diagnosis and prognosis of
ovarian cancer. There are 8 microRNAs (miR-21, miR-141,
miR-200a, miR-200b, miR-200c, miR-203, miR-205 and
miR-214) that are confirmed to be diagnostic [12]. The
levels of these microRNAs in serum differ slightly between
the early and late stages of ovarian cancer, but differ signifi-
cantly between exosomes from individuals with benign dis-
ease and those with advance stages of malignancy. Specific
microRNAs have been profiled from a direct tumor tissue
samples and compared to microRNAs from exosomes from
the peripheral circulation. Results showed that the micro-
RNA from tumor-derived exosomes are a correct reflection
of the microRNA from the tumor, indicating that profiling
the exosomal microRNA may serve as a useful tool for
early diagnosis of this deadly disease instead of sampling of
ovarian cancer tissues [12].
Exosomes in immune tolerance
While some exosomes have demonstrated immune-
stimulatory effects, whereas, others, such as exosomes
released by intestinal epithelial cells have demonstrated
the ability to induce antigen-specific tolerance. In a key
study by Karlsson, these so-called “tolerosomes” were
shown to carry MHC II molecules and thus assist the
body in building a tolerance to food antigens [36]. Exo-
somes have also been reported to stimulate an immune
tolerance during pregnancy [79-82].
Interestingly, in contrast to intestinal epithelial cell-
derived exosomes helping to create antigen-specific tol-
erance, exosomes released from dendritic cells that are
mounted with tumor peptides produce a specific anti-
tumor response in vitro in human [10]. Findings by
Andre and colleagues used exosomes from dendritic
cells that had been pulsed with tumor peptides showed a
tumor-rejection effect in patients with melanoma, pros-
tate cancer, lymphoma, and renal cancer [33], indicating
that exosomes secreted by tumor cells have the ability to
stimulate an anti-tumor response by transferring tumor-
specific antigens to dendritic or other antigen-presenting
cells, initiating a specific immune response and thus
have much potential in cancer immunotherapy [10,11].
In order for a T cell-mediated immune response to a
tumor to occur, the antigen-presenting dendritic cells
must be presented and then process a tumor antigen,
which then may be cross-presented on MHC-I mole-
cules to activate a T cell response, which has been dem-
onstrated in an in vitro model [37].
In addition to exosomes acting as immune-stimulants,
they have also demonstrated the ability to encourage toler-
ance in the immune system. Exosomes introduced to a pa-
tient from a donor prior to transplant surgery allow the
patient longer transplant acceptance time by the immune
system [71]. Studies using a rat model have shown that rat
treated with bone marrow-derived exosomes prior to a
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body production, but also experienced a decreased anti-
donor T cell response, and longer graft survival [83].
Another means of tumor promotion by exosomes is their
capability to suppress the immune response. Experiments
performed by Liu et al. [84] indicated an exosome-
mediated reduction of natural killer (NK) T cells, unrelated
to actions of T-regulatory cells. The same group found
tumor exosomes derived from myeloid-derived suppressor
cells (MDSCs) [85] and Clayton and colleagues found
tumor exosomes derived from mesothelioma [85] to ex-
press (membrane-associated) Transforming Growth Factor-
β (TGFβ1). Instead of acting as a cell cycle regulator in nor-
mal cells to induce apoptosis or cease cell proliferation,
TGFβ1 from tumor exosomes assists in immune response
evasion by tumor cells and also induces an antiproliferative
effect on tumor growth and lymphocytes. The exosomal,
membrane-associated form of TGFβ1 was more potent in
its inhibitory effect than the soluble form at significantly
lower doses [86].
Another proposed method of immune evasion by
tumor exosomes is induction of T cell apoptosis. It is
known that tumor exosomes are able to inhibit T cell
proliferation. Many cancers coincide with notable
amounts of Fas Ligand (FasL), which is correlated with
poor prognosis [87]. FasL is a transmembrane protein in
the tumor necrosis factor family. FasL is found in the
membrane of exosomes that are released from tumors
and it has been concluded that FasL does induce apop-
tosis of T cells, suppressing the immune response
[16,85,88,89].
Another mechanism of immune defense involves
antigen-presenting cells. Dendritic cell-derived exosomes
express MHC I and II and T cell co-stimulatory molecules
and deliver these complexes to dendritic cells, which are
capable of activating CD4+ and CD8+ T cells and suppress-
ing tumor growth [16,90,91] (Table 1). However, if antigen-
presenting cells such as dendritic cells are not involved,
tumor-derived exosomes may possess a self-promoting
function. Studies have recently stressed the importance of
microvesicles (exosomes) secreted by tumor cells an im-
portant means of communication between tumor cells and
their environment.
Exosomes and microvesicles
In this review we focused on exosomoes that are secreted
from the inner cell membrane compartment. We did not
discuss involvement of larger vesicles (100 nm-1μm) that
are secreted from the cell surface membranes. Augmenting
evidence indicates that both types of vesicles - smaller (exo-
somes) and larger (microvesicles) are secreted from the ac-
tivated cells. Since ovarian cancer cells express highly tissue
factor (TF) [92], they can easily activate blood platelets that
are rich source of both exosomes and microvesicles. It hasbeen demonstrated that TF-directed activation of platelets
enhances in exosome/microvesicle-dependent manner me-
tastasis of several types of cancer cells [86,93,94]. Moreover,
a concept has been presented that tumor growth and ex-
pansion is directed by a network of extracellular vesicles se-
creted by various types of normal and malignant cells
present in tumor microenvironment [95]. Its involvement
in progression of ovarian cancer needs further studies.Exosomes and therapies
Research and clinical studies have already proven exosomes
to be an accessible and reliable source of biomarkers and
early diagnosis of disease, with many more avenues yet to
be explored. Exosomes bode well in their role as a means of
intercellular communication; they contain many different
sets of molecules that have roles in various cellular pro-
cesses and possess the ability to carry antigenic information.
They have the advantage of being nonliving and they are
easily recovered from biological fluids [15]. Perhaps the
most advantageous of exosomal possibilities is their poten-
tial to serve as a key factor in finding a cure for cancer.
Tumor-derived exosomes have been used to carry tumor
antigens and present them to T cells, priming them to in-
duce the anti-tumor response, resulting in tumor cell death
[10,15,62]. Their ability to do this suggests that tumor-
derived exosomes may be useful in developing a cell-free
anti-cancer vaccine [96,97].
With the growing knowledge of exosomes functions
and the inner workings of the immune response, immu-
notherapeutic treatments are continuously being investi-
gated and developed. Vaccines are being created on the
basis of the knowledge of antigen presenting dendritic
cells that have the ability to activate CD4+ and CD8+ T
cells, as well as natural killer cells. In a phase I clinical
trial, dendritic cell exosomes demonstrated the ability to
activate NK cell proliferation and activation, shown by
an increased quantity of circulating NK cells in patients.
By observing such role of exosomes, it is plausible that
in near future, a cell-free anticancer vaccine will be
available.Conclusions
Because of multiple biological and therapeutic functions of
exosomes, studies on application of exosomes are moving
forward with new applications of exosomes. Identification
of new proteins and biomolecules in exosomes and novel
mechanisms by which they communicate and deliver their
functions are of great interest for diagnosis, drug delivery
and therapeutic purposes.Competing interests
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